Gahan Jeffrey C, Richter Michael D, Seideman Casey A, Trimmer Clayton, Chan Danny, Weaver Matthew, Olweny Ephrem O, Cadeddu Jeffrey A
Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX.
Department of Radiology, University of Texas Southwestern Medical Center, Dallas, TX.
Urology. 2015 Jan;85(1):125-9. doi: 10.1016/j.urology.2014.08.026. Epub 2014 Oct 18.
To assess the predictive performance of a modified RENAL nephrometry score for renal tumors undergoing radiofrequency ablation (RFA).
Patients who underwent RFA were identified from 2002 to 2011, and RENAL nephrometry scoring was performed for each. A modified RENAL (m-RENAL) nephrometry score was created to account for the small sizes of tumors ablated for which the size variable, R, was adjusted. A size of 3 cm was calculated as the optimal cutoff for the R component of the m-RENAL nephrometry score, and tumors were given an R score of 1 if <3 cm, 2 if 3-4 cm, or 3 if >4 cm. Other RENAL variables were unchanged. Oncologic outcomes were stratified by complexity tertiles defined as low (4-6), medium (7-9), and high (10-12). Outcomes were reported as initial ablation success (IAS), recurrence-free survival (RFS), and metastatic-free survival (MFS). The Kaplan-Meir method was used to estimate survival based on complexity tertile.
Two hundred forty patients were identified who underwent RFA, of which 192 patients were eligible for analysis. Median follow-up was 32.2 months, and median tumor size was 2.4 cm. IAS was achieved in 185 of 192 patients (96.4%). Overall, the estimated 3-year RFS was 95.1% and MFS was 97.3%. There was no statistical difference between complexity tertiles using the standard RENAL nephrometry score; however, the m-RENAL nephrometry score was significantly associated with IAS and RFS (P = .027 and P = .003, respectively). There were too few events (n = 3) to perform statistical analysis for MFS.
A modification to the size variable increases the performance of the RENAL nephrometry score when used to stratify RFA ablation success.
评估改良的RENAL肾计量评分对接受射频消融(RFA)的肾肿瘤的预测性能。
确定2002年至2011年间接受RFA的患者,并对每位患者进行RENAL肾计量评分。创建了改良的RENAL(m-RENAL)肾计量评分,以考虑因消融肿瘤体积较小而对大小变量R进行调整的情况。计算出3 cm作为m-RENAL肾计量评分R分量的最佳截断值,肿瘤<3 cm时R评分为1,3 - 4 cm时为2,>4 cm时为3。其他RENAL变量保持不变。肿瘤学结局按定义为低(4 - 6)、中(7 - 9)和高(10 - 12)的复杂性三分位数进行分层。结局报告为初次消融成功(IAS)、无复发生存率(RFS)和无转移生存率(MFS)。采用Kaplan-Meir方法根据复杂性三分位数估计生存率。
确定了240例接受RFA的患者,其中192例患者符合分析条件。中位随访时间为32.2个月,中位肿瘤大小为2.4 cm。192例患者中有185例(96.4%)实现了IAS。总体而言,估计3年RFS为95.1%,MFS为97.3%。使用标准RENAL肾计量评分时,复杂性三分位数之间无统计学差异;然而,m-RENAL肾计量评分与IAS和RFS显著相关(分别为P = 0.027和P = 0.003)。事件数太少(n = 3),无法对MFS进行统计分析。
对大小变量进行修改可提高RENAL肾计量评分用于分层RFA消融成功情况时的性能。